CAR-T Therapy for Non-Hodgkin Lymphoma (NHL)
Overview
Non-Hodgkin Lymphoma (NHL) is a diverse group of blood cancers originating in the lymphatic system, with various subtypes, including B-cell and T-cell lymphomas. Among these, Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive form of B-cell NHL. Despite advancements in chemotherapy and immunotherapy, many patients with relapsed or refractory NHL struggle with limited treatment options. CAR-T therapy offers a breakthrough approach, providing hope for patients whose lymphoma has not responded to traditional therapies.
What is CAR-T Therapy for NHL?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary immunotherapy that involves modifying a patient’s T-cells to express a receptor that targets cancerous cells. For NHL, CAR-T therapy primarily targets CD19 and CD20 antigens on B-cells, which are commonly found on malignant lymphoma cells. By enhancing the T-cells’ ability to recognize and attack these cancer cells, CAR-T therapy offers an effective treatment option for patients with relapsed or refractory lymphoma.
Key Benefits of CAR-T Therapy for NHL
- Effective for Relapsed and Refractory NHL: CAR-T therapy has shown exceptional efficacy in patients with DLBCL and other forms of B-cell NHL who have not responded to multiple lines of treatment.
- Targeted Precision: The therapy targets cancerous B-cells without harming healthy cells, reducing the side effects often associated with traditional therapies.
- Personalized Treatment: CAR-T therapy uses the patient's own T-cells, offering a customized treatment approach that is tailored to the individual’s specific condition.
- Potential for Long-Term Remission: Many patients have achieved complete or partial remission after CAR-T therapy, with some maintaining long-term survival, even after multiple rounds of chemotherapy.
Treatment Process
- T-cell Collection: T-cells are harvested from the patient’s blood through a process called leukapheresis, similar to blood donation.
- Engineering the T-cells: In the laboratory, the collected T-cells are genetically modified to express receptors that target specific antigens like CD19 or CD20 found on lymphoma cells.
- CAR-T Infusion: Once the T-cells are expanded and modified, they are infused back into the patient’s bloodstream to attack the lymphoma cells.
- Monitoring and Recovery: After the infusion, patients are monitored for side effects, such as cytokine release syndrome (CRS) and neurotoxicity, both of which can be managed with appropriate medical intervention.
Why Choose BIOOCUS's CAR-T Therapy for NHL?
- State-of-the-Art CAR-T Technology: BIOOCUS employs cutting-edge CAR-T technology to offer the most advanced and effective treatment for NHL, utilizing the latest research to ensure optimal outcomes.
- Expert Hematology Team: Our multidisciplinary team of hematologists, oncologists, and immunotherapy specialists work together to provide personalized treatment plans for each patient.
- Proven Success in Treating DLBCL: BIOOCUS has treated numerous NHL patients with CAR-T therapy, achieving remarkable responses, including complete remission and durable survival, especially in patients with relapsed or refractory DLBCL.
- Comprehensive Patient Support: From initial consultation to post-treatment care, BIOOCUS offers comprehensive support to international patients, ensuring a smooth and supportive journey throughout their treatment process.
Clinical Evidence and Success Rates
-
CAR-T therapy for NHL, particularly for DLBCL, has shown outstanding results in clinical trials and real-world applications. For patients who have undergone multiple lines of therapy without success, CAR-T therapy has proven to be a life-saving option.
- Patient Story: Diffuse Large B-Cell Lymphoma (DLBCL)—A Remarkable Recovery After CAR-T Therapy
- Clinical Success: CAR-T Therapy for Relapsed DLBCL—A Path to Complete Remission
- Multi-Line Resistant DLBCL: A Case Study of CAR-T Therapy’s Efficacy in Advanced Lymphoma
These case studies highlight the transformative potential of CAR-T therapy for patients with NHL, especially those with aggressive and multi-line resistant DLBCL. Many patients have achieved long-term remission and have regained quality of life following treatment.
Clinical Data
Indications for CD19+20CAR-T: Patients with B-cell non Hodgkin's lymphoma
|
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
|
71.95%（59/82） |
25.6（21/82） |
97.55（80/82） |
12.19%（10/82） |
0 |
Indications for CD19+22CAR-T: Treatment of CD19 relapsed and refractory acute B-lymphocytic leukemia patients
|
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
|
92.1%（35/38） |
7.9%（3/38） |
100%（38/38） |
15.79%（6/38） |
0 |
Indications for BCMACAR-T: Treatment of relapsed and refractory multiple myeloma
|
One month CR rate |
One month PR rate |
One month OR rate |
CRS≥3 |
CRES≥3 |
|
72.41%（21/29） |
27.59%（8/29） |
100%（29/29） |
6.9%（2/29） |
0 |